Regenerating Retinal Pigment Epithelial Cells to Cure Blindness: A Road Towards Personalized Artificial Tissue.

Autor: Jha BS; Unit on Ocular and Stem Cell Translational Research, National Eye Institute, 10 Center Drive, Room 10B10, Bethesda, MD 20892, USA., Bharti K; Unit on Ocular and Stem Cell Translational Research, National Eye Institute, 10 Center Drive, Room 10B10, Bethesda, MD 20892, USA.
Jazyk: angličtina
Zdroj: Current stem cell reports [Curr Stem Cell Rep] 2015 Jun; Vol. 1 (2), pp. 79-91.
DOI: 10.1007/s40778-015-0014-4
Abstrakt: Retinal pigment epithelium (RPE) is a polarized monolayer tissue that functions to support the health and integrity of retinal photoreceptors (PRs). RPE atrophy has been linked to pathogenesis of age-related macular degeneration (AMD), a leading cause of blindness in elderly in the USA. RPE atrophy in AMD leads to the PR cell death and vision loss. It is thought that replacing diseased RPE with healthy RPE tissue can prevent PR cell death. Retinal surgical innovations have provided proof-of-principle data that autologous RPE tissue can replace diseased macular RPE and provide visual rescue in AMD patients. Current efforts are focused on developing an in vitro tissue using natural and synthetic scaffolds to generate a polarized functional RPE monolayer. In the future, these tissue-engineering approaches combined with pluripotent stem cell technology will lead to the development of personalized and "off-the-shelf" cell therapies for AMD patients. This review summarizes the historical development and ongoing efforts in surgical and in vitro tissue engineering techniques to develop a three-dimensional therapeutic native RPE tissue substitute.
Databáze: MEDLINE
Externí odkaz: